ACS Medicinal Chemistry Letters · 2022 · 32 citations · 30 references
PharmacyChemistryMedicinal ChemistryDrug DesignDrug DiscoveryStructural BiologyLigand BindingLigand-based DesignProtein-ligand BindingProtein-ligand InteractionsProtein-ligand RecognitionRna StructureBinding Affinity EnhancementBinding Mode AnalysisBinding Mode OptimizationBinding Mode PredictionFluorescence-based AssaysFragment-based Ligand DesignLigand-binding Assay ValidationStructure-based Binding Mechanisms
We report 17 small-molecule ligands that compete with N6-methyladenosine (m6A) for binding to the m6A-reader domain of YTHDF2 (YT521-B homology domain family 2). We determined their binding mode at high resolution by X-ray crystallography and quantified their affinity by a fluorescence-based binding assay. 6-Cyclopropyluracil and a pyrazolopyrimidine derivative have favorable ligand efficiencies of 0.47 and 0.38 kcal mol–1 per non-hydrogen atom, respectively. They represent useful starting points for hit optimization.
30
Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq
Dan Dominissini, Sharon Moshitch-Moshkovitz, Schraga Schwartz et al. · Nature · 2012 · 5K citations
N6-methyladenosine-dependent regulation of messenger RNA stability
Xiao Wang, Zhike Lu, Adrian Gomez-Nguyen et al. · Nature · 2013 · 4.8K citations
A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation
Jianzhao Liu, Yanan Yue, Dali Han et al. · Nature Chemical Biology · 2013 · 3.5K citations · Full text
Hao Du, Ya Zhao, Jinqiu He et al. · Nature Communications · 2016 · 1.5K citations · Full text